None
Quote | Aquestive Therapeutics Inc. (NASDAQ:AQST)
Last: | $2.48 |
---|---|
Change Percent: | 0.0% |
Open: | $2.41 |
Close: | $2.48 |
High: | $2.48 |
Low: | $2.36 |
Volume: | 1,143,974 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Aquestive Therapeutics Inc. (NASDAQ:AQST)
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
2024-06-25 14:10:10 ET Summary ARS Pharmaceuticals stock has recovered since the FDA's Complete Response Letter regarding its epinephrine nasal spray, neffy. Despite competition and a delayed market entry, ARS Pharmaceuticals remains ahead with its unique nasal spray, aiming for a...
Message Board Posts | Aquestive Therapeutics Inc. (NASDAQ:AQST)
Subject | By | Source | When |
---|---|---|---|
Toxic slobs is more like it. | trendzone | investorshub | 09/27/2022 9:59:43 PM |
On going S-3 shelf placement! | crudeoil24 | investorshub | 09/27/2022 11:33:33 AM |
Aquestive Therapeutics Announces EPIPHAST II Trial Data For | crudeoil24 | investorshub | 09/27/2022 11:29:53 AM |
znewcar1: AQST 24% v2,2M c1.73 f53,4M H1.78 ML.78 LL.62 nice turn Haft1.98 | znewcar1 | investorshangout | 08/12/2022 8:48:36 PM |
https://www.stockscores.com/chart.asp?TickerSymbol=aqst%20&TimeRange=1825&Interv | The Night Stalker | investorshub | 07/23/2022 4:56:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pH Remains on track to complete Anaphylm supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024 Continues to anticipate filin...
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...